Autolus Therapeutics (NASDAQ:AUTL) Sets New 1-Year High - Still a Buy?Market Beat·Aug 19 at 10:00 AMAUTL+1.93%IVZ+1.56%
Autolus publishes corporate presentation on next-generation programmed T-cell therapies, led by AUCATZYL franchise expansionPUBT·Aug 18 at 11:17 AMAUTL+1.93%
U.S. stock market midday update: Autolus down 9.87%: Revenue doubles but losses remain, analysts cautious on ratingsPrice Alert·Aug 12 at 02:38 PMAUTL+1.93%
10:31 ETCAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsightprnewswire·Aug 12 at 09:31 AMCLLS+3.65%AUTL+1.93%
Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Estimates By $0.06 EPSMarket Beat·Aug 11 at 09:26 AMAUTL+1.93%
AUTL: Q2 2026 revenue up 119% year-over-year, gross margin at 55%, FY guidance raisedQuartr·Aug 11 at 06:39 AMAUTL+1.93%
Autolus Q2 net loss narrows 18.38% to $39.11 million; net product revenue more than doubles 119% to $45.7 millionPUBT·Aug 11 at 06:04 AMAUTL+1.93%
Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentumrttnews·Aug 3 at 09:33 PMXAIR-7.24%CAMP+4.05%
Autolus Therapeutics schedules second-quarter financial results release and conference callPUBT·Aug 3 at 03:09 PMAUTL+1.93%
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy?Market Beat·Aug 3 at 12:40 PMAUTL+1.93%
